BiotechTube
Home/Pipeline/Undisclosed Kinase Inhibitor Program(s)

Undisclosed Kinase Inhibitor Program(s)

Oncology (unspecified)

Phase 3Active

Key Facts

Indication
Oncology (unspecified)
Phase
Phase 3
Status
Active
Company
Advenchen Laboratories

About Advenchen Laboratories

Advenchen Laboratories is a private, preclinical to late-stage clinical biotech founded in 2005 and headquartered in Monrovia, California. The company's core expertise lies in designing innovative chemical scaffolds to develop small molecule kinase inhibitors targeting various cancers, with several programs reported to be in Phase 3 clinical studies. With a focused R&D model and a targeted first NDA submission in 2025, Advenchen is positioning itself to transition from a research-oriented entity to a potential commercial-stage company in the competitive oncology therapeutics space.

View full company profile

Therapeutic Areas

Oncology

Other Oncology (unspecified) Drugs

DrugCompanyPhase
Oncology Vaccine ProgramCHAIN BiotechPre-clinical
ARX305NovoCodex BiopharmaceuticalsPhase 1
ARX788NovoCodex BiopharmaceuticalsPhase 1
Cancer Immunotherapy NanotherapeuticFlashpoint TherapeuticsPhase 1
GRWD5769Greywolf TherapeuticsPhase 1/2
Platform-derived Program(s)Immuto ScientificDiscovery/Pre-clinical
MBT Oncology ProgramIonic PharmaceuticalsPre-clinical
ISB 2301Ichnos Glenmark InnovationPreclinical
GRC 65327Ichnos Glenmark InnovationPreclinical
Platform-Derived PipelinePhinomicsDiscovery/Pre-clinical
Lead Small-Molecule InhibitorEris BiotechPre-clinical
Orotecan™Edison OncologyPhase 1/2a